Objective
The objective of the EUCF-PHVD programme provide highly skilled scientific personnel with primate research expertise with the resources for the stepwise development and evaluation of safe, effective viral vaccines, and specifically vaccines for the prevention of HIV- 1 infection and development of AIDS.
Phase "A" of the EUCF-PHVD programme is a limited part of the EUCE-PHVD proposal ranked number 1 by the European Commission in 1995 against a large number of other competitive proposals in the same area. Due to limited funds only phase "A" (approximately 1/5th) of the scope of the entire proposal could be initiated. The Commission has requested that the remainder of the EUCF-PHVD programme (phase "B") be resubmitted (the same objective but additional vaccines/strategies which need to be evaluated) for the second round of BIOMED II. The broad aims of the EUCF-PHVD programme are to provide European researchers with a critical competitive research resource for the development and evaluation of Vaccine Biotechnology initiatives. It is the aim to accelerate the preclinical development and evaluation of European vaccine candidates as effective products to the clinic. This expert staff will utilise the unique resources of the Biomedical Primate Research Centre and lend their expertise to provide European Researchers with valuable assistance to facilitate strategic development and to improve vaccine efficacy. All non human primate (NHP) studies will all be performed at the Centralised Facility for the sake of standardisation and comparison, including cell-mediated immunity and virus detection assays. Serologic assays will be performed by the collaborating partners whenever possible, but retrospective analysis and comparison of responses across or between studies will be performed by the EUCF-PHVD personnel or a designated unbiased third party. Decisions on which studies should go onto chimpanzees, and when or if chimpanzees should be challenged will be made by the EUCF-PHVD Scientific Advisory Committee (SAC) on the basis of standardised studies and readouts performed at the EUCF-PHVD.
In phase "A" the Centralised Facility will provide the resources and expertise to European Vaccine Researchers participating in this phase of the programme. If successful at inducing the desired immune response in rhesus monkeys (and if applicable protection from virus challenge), then it may be recommended to evaluate this candidate further in chimpanzees prior to clinical trials.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- natural sciences biological sciences microbiology virology
- medical and health sciences basic medicine immunology
- medical and health sciences health sciences infectious diseases RNA viruses HIV
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs vaccines
You need to log in or register to use this function
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Data not available
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
2288 GJ Rijswijk
Netherlands
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.